Pharmaceutical Preparations · DE · CIK 1810182
Develops immuno-oncology treatments, like evorpacept, to help patients fight cancer by blocking CD47 signals
Comparable business profile · signals at a glance
In the 90 days to Mar 19, 2026: 1 insider bought $5.0M · 2 sold $34K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 19, 2026 | Lettmann JasonCHIEF EXECUTIVE OFFICER | Sell | 12,311 | $2.17 | $27K |
| Mar 19, 2026 | Pinto ShellySVP, FINANCE AND CAO | Sell | 903 | $2.17 | $2K |
| Feb 18, 2026 | Pinto ShellySVP, FINANCE AND CAO | Sell | 565 | $2.27 | $1K |
| Feb 2, 2026 | Goodman Corey SDirector,TenPercentOwner | Buy | 3,184,713 | $1.57 | $5.0M |
| Jan 6, 2026 | Pinto ShellySVP, FINANCE AND CAO | Sell | 3,925 | $1.11 | $4K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.